All In MedTech

FDA Clearance Tracker · P200041

Scoreflex NC Scoring PTCA Catheter

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Dec 21, 2021 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Dec 21, 2021

Approved

Time to decision

468 days

Received Sep 9, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P200041
Device name
Scoreflex NC Scoring PTCA Catheter
Applicant location
Shenzhen
Received
Sep 9, 2020
Decided
Dec 21, 2021
Decision
Approved
Supplements
9 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NWX

FDA's approval statement

As written in FDA's record.

Approval for the Scoreflex NC Scoring PTCA Catheter. The device is indicated for: Balloon dilatation of a de novo stenotic portion of a coronary artery and in-stent restenosis in coronary arteries in patients evidencing coronary ischemia for the purpose of improving myocardial perfusion.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NWX. The earliest in FDA's data is P950020, decided Apr 18, 2000.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for OrbusNeich Medical (Shenzhen) Co., Ltd.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.